Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Madrigal Pharmaceuticals	MacroGenics	Seres Therapeutics	Kura Oncology	CytoDyn
Symbol	NASDAQ:MDGL	NASDAQ:MGNX	NASDAQ:MCRB	NASDAQ:KURA	OTCMKTS:CYDY
Price Information
Current Price	$132.05	$30.48	$22.60	$25.39	$2.80
52 Week Range	Buy	Buy	Buy	Buy	Hold
MarketRank™
Overall Score	1.7	1.4	1.7	1.6	1.1
Analysis Score	3.4	2.4	3.4	3.5	3.0
Community Score	2.8	2.5	3.0	2.7	2.6
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	2.5	1.7	1.7	1.7	0.0
Earnings & Valuation Score	0.0	0.6	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Hold
Consensus Price Target	$167.60	$34.30	$39.00	$39.45	$4.00
% Upside from Price Target	26.92% upside	12.53% upside	72.57% upside	55.39% upside	42.86% upside
Trade Information
Market Cap	$2.17 billion	$1.83 billion	$1.84 billion	$1.64 billion	$1.73 billion
Beta	1.19	2.4	4.07	2.15	-0.64
Average Volume	165,603	773,997	974,209	712,173	4,236,808
Sales & Book Value
Annual Revenue	N/A	$64.19 million	$34.51 million	N/A	N/A
Price / Sales	N/A	28.51	60.00	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$27.00 per share	$4.71 per share	($0.69) per share	$4.83 per share	($0.01) per share
Price / Book	N/A	6.47	-32.75	N/A	N/A
Profitability
Net Income	$-83,950,000.00	$-151,810,000.00	$-70,280,000.00	$-63,140,000.00	$-124,400,000.00
EPS	($5.45)	($3.16)	($1.20)	($1.51)	($0.21)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-204.31%	-385.22%	N/A	N/A
Return on Equity (ROE)	-47.64%	-65.84%	-2,867.98%	-30.96%	N/A
Return on Assets (ROA)	-43.21%	-49.41%	-51.24%	-28.02%	-153.30%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	N/A	0.13%	0.02%	5.01%
Current Ratio	6.84%	6.19%	6.73%	15.15%	1.13%
Quick Ratio	6.84%	6.19%	6.73%	15.15%	0.28%
Ownership Information
Institutional Ownership Percentage	74.24%	95.80%	94.32%	94.72%	0.10%
Insider Ownership Percentage	41.89%	9.00%	4.80%	11.00%	7.80%
Miscellaneous
Employees	42	370	155	88	19
Shares Outstanding	16.49 million	60.04 million	91.62 million	66.27 million	619.04 million
Next Earnings Date	8/5/2021 (Estimated)	7/29/2021 (Estimated)	7/27/2021 (Estimated)	8/5/2021 (Estimated)	8/13/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Optionable	Not Optionable

Source	Headline
	ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CYDY - Yahoo Finance finance.yahoo.com - May 10 at 7:50 PM
	CYDY Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds CytoDyn, Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: May 17, 2021 - Yahoo Finance finance.yahoo.com - May 10 at 7:50 PM
	CYDY DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit - Yahoo Finance finance.yahoo.com - May 10 at 2:49 PM
	CYDY DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit feeds.benzinga.com - May 9 at 4:05 PM
	CytoDyn (CYDY) Stock Consolidates In Absence Of Any Catalyst – Own Snap - Own Snap ownsnap.com - May 9 at 1:28 PM
	Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc. - Clearfield Progress theprogressnews.com - May 9 at 12:34 AM
	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY - Marketscreener.com marketscreener.com - May 8 at 7:30 PM
	Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc. prnewswire.com - May 8 at 3:06 PM
	Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc. - Bradford Era bradfordera.com - May 8 at 2:17 PM
	Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against CytoDyn Inc. finance.yahoo.com - May 8 at 2:17 PM
	CytoDyn (OTCMKTS:CYDY) Shares Up 8.2% americanbankingnews.com - May 8 at 12:16 AM
	CytoDyn strikes agreement with AEIH in Brazil to run two coronavirus trials using its flagship drug leronlimab - Proactive Investors USA & Canada proactiveinvestors.com - May 7 at 8:00 PM
	CytoDyn, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Stockhouse stockhouse.com - May 7 at 3:00 PM
	SHAREHOLDER ALERT: CYDY KRMD CCXI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines finance.yahoo.com - May 7 at 3:00 PM
	CytoDyn's Leronlimab Featured on OneNews in Philippines on May 9 - GlobeNewswire globenewswire.com - May 7 at 9:59 AM
	CytoDyn’s Leronlimab Featured on OneNews in Philippines on May 9 finance.yahoo.com - May 7 at 9:59 AM
	CytoDyn and AEIH to begin trials of leronlimab in severe Covid-19 - Clinical Trials Arena clinicaltrialsarena.com - May 6 at 6:21 PM
	Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. - Yahoo Finance finance.yahoo.com - May 6 at 1:20 PM
	CytoDyn: Suitable For Trading Not Investing - Seeking Alpha seekingalpha.com - May 6 at 1:20 PM
	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CYDY, NEPT and ACAD finance.yahoo.com - May 6 at 1:20 PM
	ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages CytoDyn Inc. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action - CYDY - Yahoo Finance finance.yahoo.com - May 5 at 11:52 PM
	Lawsuits Filed Against CYDY, DOX and PTON - Jakubowitz Law Pursues Shareholders Claims finance.yahoo.com - May 5 at 6:48 PM
	CYDY Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit - Yahoo Finance finance.yahoo.com - May 5 at 1:48 PM
	CYDY DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against CytoDyn, Inc. – CYDY - Yahoo Finance finance.yahoo.com - May 5 at 1:48 PM
	CYDY Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit finance.yahoo.com - May 5 at 1:48 PM

Date	Company	Brokerage	Action
3/4/2021	Madrigal Pharmaceuticals	Chardan Capital	Boost Price Target
3/2/2021	Madrigal Pharmaceuticals	Oppenheimer	Lower Price Target
11/23/2020	Madrigal Pharmaceuticals	Evercore ISI	Reiterated Rating
11/12/2020	Madrigal Pharmaceuticals	Canaccord Genuity	Lower Price Target
11/6/2020	Madrigal Pharmaceuticals	The Goldman Sachs Group	Boost Price Target
11/6/2020	Madrigal Pharmaceuticals	BMO Capital Markets	Boost Price Target
11/6/2020	Madrigal Pharmaceuticals	HC Wainwright	Boost Price Target
11/5/2020	Madrigal Pharmaceuticals	Piper Sandler	Lower Price Target
8/6/2020	Madrigal Pharmaceuticals	Stifel Nicolaus	Reiterated Rating
5/22/2020	Madrigal Pharmaceuticals	B. Riley	Boost Price Target
3/5/2020	Madrigal Pharmaceuticals	Citigroup	Lower Price Target
5/6/2021	MacroGenics	SVB Leerink	Boost Price Target
5/3/2021	MacroGenics	Morgan Stanley	Boost Price Target
3/18/2021	MacroGenics	Barclays	Upgrade
6/1/2020	MacroGenics	Guggenheim	Upgrade
12/23/2020	Seres Therapeutics	JMP Securities	Initiated Coverage
8/11/2020	Seres Therapeutics	Jefferies Financial Group	Upgrade
5/5/2021	Kura Oncology	Credit Suisse Group	Initiated Coverage
12/7/2020	Kura Oncology	Wedbush	Boost Price Target
10/8/2020	Kura Oncology	CSFB	Boost Price Target
8/16/2020	Kura Oncology	Brookline Capital Management	Reiterated Rating
5/19/2020	Kura Oncology	Deutsche Bank Aktiengesellschaft	Lower Price Target

(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources